The probiotic bacterium (blue) with Shiga toxin (red) bound all over its surface.
A potential life-saving treatment for severe E. coli-related food poisoning outbreaks developed more than a decade ago hasn't gone forward into clinical trials because of lack of commercial interest.
University of Adelaide researchers produced a "designer" probiotic bacterium which binds and neutralises the toxin produced by E. coli, which causes life-threatening attack on the kidneys and blood vessels.
The team of scientists Dr. Adrienne Paton, associate professor Renato Morona and professor James Paton showed that mice infected with a highly virulent strain of E. coli were completely protected by the probiotic bacterium.
The research was published in the prestigious journal Nature Medicine in 2000 and generated ongoing interest from the scientific and medical community but the commercial sector hasn't taken up its development for progress into clinical trials in humans.
"Severe E. coli food poisoning outbreaks such as that currently occurring in Europe are becoming increasingly common," says Paton, director of the Research Centre for Infectious Diseases at the University of Adelaide. "They have the potential to cause widespread disease and many patients develop life-threatening complications including kidney failure. The probiotic bacterium could be produced cheaply on a large scale. However, in spite of on-going attention from the scientific and medical community, there has been a lack of interest from the commercial sector in taking this product forward into clinical trials. If this had been done, and the probiotic had been proven to be safe and efficacious in humans, it could have been deployed during the current European outbreak. This would undoubtedly have saved lives, as well as millions of dollars in current and future healthcare costs."
The researchers engineered a harmless bacterium to mimic binding receptors for the potentially fatal Shiga toxin on its surface.
Paton says after diagnosis of E. coli infection there was a window of opportunity for therapeutic intervention before kidneys started to fail. Antibiotics are not used because they can increase the amount of toxin released in the gut.
Redefining Competency: A Comprehensive Framework for Infection Preventionists
December 19th 2024Explore APIC’s groundbreaking framework for defining and documenting infection preventionist competency. Christine Zirges, DNP, ACNS-BC, CIC, FAPIC, shares insights on advancing professional growth, improving patient safety, and navigating regulatory challenges.
Addressing Post-COVID Challenges: The Urgent Need for Enhanced Hospital Reporting Metrics
December 18th 2024Explore why CMS must expand COVID-19, influenza, and RSV reporting to include hospital-onset infections, health care worker cases, and ER trends, driving proactive prevention and patient safety.
Announcing the 2024 Infection Control Today Educator of the Year: Shahbaz Salehi, MD, MPH, MSHIA
December 17th 2024Shahbaz Salehi, MD, MPH, MSHIA, is the Infection Control Today 2024 Educator of the Year. He is celebrated for his leadership, mentorship, and transformative contributions to infection prevention education and patient safety.
Pula General Hospital Celebrates Clean Hospitals
December 16th 2024Learn how Pula General Hospital in Croatia championed infection prevention and environmental hygiene and celebrated Clean Hospitals Day to honor cleaning staff and promote advanced practices for exceptional patient care and safety.
Understanding NHSN's 2022 Rebaseline Data: Key Updates and Implications for HAI Reporting
December 13th 2024Discover how the NHSN 2022 Rebaseline initiative updates health care-associated infection metrics to align with modern health care trends, enabling improved infection prevention strategies and patient safety outcomes.